We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Risk Loci Identified for Polycystic Ovary Syndrome

By LabMedica International staff writers
Posted on 09 Jan 2019
Polycystic ovary syndrome is a disorder characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology. More...
Affected women frequently have metabolic disturbances including insulin resistance and dysregulation of glucose homeostasis.

Polycystic ovary syndrome (PCOS) is diagnosed with two different sets of diagnostic criteria, resulting in a phenotypic spectrum of PCOS cases. The genetic similarities between cases diagnosed based on the two criteria have been largely unknown.

An international team of scientists working with the University of Utah (Salt Lake City, UT) performed a genome-wide association study meta-analysis involving 10,074 individuals with PCOS and 103,164 without, leading to three previously undetected loci and 11 loci linked to the endocrine disorder in the past. Of those, 13 loci were associated with self-reported PCOS and cases diagnosed using National Institutes of Health or Rotterdam criteria.

PCOS diagnoses are based on excess androgen hormone levels and ovulatory dysfunction, the team explained, which represents roughly 7% of reproductive age women around the world. On the other hand, more general criteria from Rotterdam defined PCOS as polycystic ovarian morphology in combination with either hyperandrogenism or ovulatory dysfunction, representing an estimated 15% to 20% of women globally.

The team reported new associations at loci in or around the PLGRKT, ZBTB16, and MAPRE1 genes, which are believed to contribute to metabolic and reproductive pathways. The meta-analysis also led to 11 known risk loci, which were overrepresented for variants in and around genes from neuroendocrine and metabolic pathways. The set of known risk loci included half a dozen sites previously implicated in PCOS in women of Han Chinese ancestry, and a variant near the GATA4/NEIL2 genes that showed strong ties to the PCOS diagnosed using NIH criteria but weaker associations to the self-reported PCOS cases.

The authors concluded that the genetic underpinnings of PCOS implicate neuroendocrine, metabolic, and reproductive pathways in the pathogenesis of disease. Although specific phenotype stratified analyses are needed, genetic findings were consistent across the diagnostic criteria for all but one susceptibility locus, suggesting a common genetic architecture underlying the different phenotypes. The study was published on December 19, 2018, in the journal PLOS Genetics.

Related Links:
University of Utah


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.